← back to search

Edward Gabrielson

Bloomberg (United States) · US
Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Epigenetics and DNA Methylation, Cancer Genomics and Diagnostics, and Radiopharmaceutical Chemistry and Applications.
h-index
70
citations
21,818
works
292
NIH funding
primary concept
email

Recent publications

Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Nature Medicine 2023cited by 156position: middledoi
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Clinical Cancer Research 2020cited by 172position: middledoi
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Clinical Cancer Research 2019cited by 152position: middledoi
DNA Methylation Markers for Breast Cancer Detection in the Developing World
Clinical Cancer Research 2019cited by 41position: middledoi
Chemotherapy induces enrichment of CD47 <sup>+</sup> /CD73 <sup>+</sup> /PDL1 <sup>+</sup> immune evasive triple-negative breast cancer cells
Proceedings of the National Academy of Sciences 2018cited by 311position: middledoi
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Cancer Research 2018cited by 310position: middledoi
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Journal of Clinical Investigation 2018cited by 139position: middledoi
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Cancer Discovery 2016cited by 893position: middledoi
Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers
American Journal Of Pathology 2014cited by 366position: middledoi
Activation of diverse signalling pathways by oncogenic PIK3CA mutations
Nature Communications 2014cited by 84position: middledoi
TBCRC 008: Early Change in <sup>18</sup>F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer
Journal of Nuclear Medicine 2014cited by 65position: middledoi
Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program
Cell 2013cited by 851position: middledoi
Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis
Journal of Clinical Investigation 2013cited by 328position: middledoi
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
Epigenetics 2012cited by 67position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shyam Biswal · Johns Hopkins University2 papers (2013–2020)Samit Chatterjee · University of Rajasthan2 papers (2018–2020)Anju Singh · University of Alabama at Birmingham2 papers (2013–2020) · 2 papers (2013–2020)Buvana Ravishankar · Parker Institute for Cancer Immunotherapy1 papers (2020–2020)Janis M. Taube · University Medical Center Hamburg-Eppendorf1 papers (2023–2023)Peter B. Illei · Swedish Medical Center1 papers (2023–2023)Georgia Hatzivassiliou · Parker Institute for Cancer Immunotherapy1 papers (2020–2020)Debangshu Samanta · SK Life Science (United States)1 papers (2018–2018)Sabine C. Glöckner · University of Regensburg1 papers (2012–2012)James G. Herman · University of Colorado Denver1 papers (2012–2012)Wayne Mitzner · Johns Hopkins Medicine1 papers (2020–2020)Kuladeep Sudini · Johns Hopkins University1 papers (2020–2020) · 1 papers (2013–2013)Maureen A. Powers · Emory University1 papers (2014–2014)Elyes Dahmane · University of Lausanne1 papers (2018–2018)Zena Werb · University of California, San Francisco1 papers (2013–2013) · 1 papers (2018–2018)Jonathan Spicer · McGill University Health Centre1 papers (2023–2023)Charles M. Rudin · New York Proton Center1 papers (2018–2018)